-
Radiopharm (ASX:RAD) Partners with Starpharma to Develop Novel Radiotherapy Asset
30 Sep 2025 01:37 GMT
… RAD’s radiopharmaceutical molecule with Starpharma’s proprietary DEP® platform … commercial and regulatory milestones. Furthermore, Starpharma will be entitled to royalties … on net sales.
About Starpharma
Starpharma is a biotechnology company with …
-
Genentech $569M deal lifts Starpharma stock 73%
22 Sep 2025 23:58 GMT
Starpharma Holdings Ltd.’s stock shot …
-
Australia's Starpharma announces collaboration worth $564 M with Genentech for cancer therapies
22 Sep 2025 15:36 GMT
… to develop dendrimer-drug conjugates
Starpharma, an Australian biotechnology company, … DEP® drug delivery technology.
Starpharma will receive an upfront payment … treatment indications.
Cheryl Maley, Starpharma Chief Executive Officer, commented, “A …
-
Starpharma Announces a Collaboration and License Agreement with Genentech
22 Sep 2025 11:30 GMT
… DEP® drug delivery technology. Starpharma will receive an upfront payment … additional treatment indications. Cheryl Maley, Starpharma Chief Executive Officer, commented: “ … developing cancer therapies utilising Starpharma’s proprietary dendrimer technology …
-
Health Check: Starpharma revs up on Big Pharma deal worth up to $855m
22 Sep 2025 04:25 GMT
… commercial and sales milestones.
Starpharma is also eligible for … market cap Roche Group.
Starpharma will develop its dendrimer … deal is based around Starpharma’s flagship dendrimer enhanced … and gastro-oesophageal tumours.
Starpharma CEO Cheryl Maley says …
-
Newmont jumps, Starpharma soars on Roche deal
22 Sep 2025 03:57 GMT
… Last
%
Volume
MktCap
SPL
Starpharma Holdings
0.215
65%
… 028,959
$42,446,503
Starpharma (ASX:SPL) has signed … therapies built on Starpharma’s DEP platform. Starpharma gets an upfront … from the collaboration, while Starpharma will run the early development …
-
FDA pushes back decision on Sanofi’s BTK inhibitor; Roche makes a deal with Starpharma
22 Sep 2025 18:48 GMT
Plus, news about Sciwind Biosciences, Ipsen, Genfit, Ascletis, AusperBio, Ensoma, Jasper Therapeutics, Verrica, Incyte and Johnson & Johnson:
🏛️ FDA delays decision on Sanofi’s tolebrutinib …
-
Top 10 at 11: ASX starts week on the up as Starpharma shines on Big Pharma deal
22 Sep 2025 01:59 GMT
…
Volume
Market Cap
SPL
Starpharma Holdings
0.235
81%
… ,329,785
WordPress Table
Starpharma (ASX:SPL) is up 81% … potential cancer therapies that leverage Starpharma’s proprietary DEP drug … technology.
Under the deal Starpharma will receive an upfront payment …
-
Herpes Simplex Market Poised for Substantial Growth by 2034, According to DelveInsight | Maruho, AiCuris, Starpharma
19 Dec 2024 11:04 GMT
… RedBioTec, TGV-Laboratories, Sanofi, Starpharma, and others, are actively … , Maruho, AiCuris, Sanofi, GlaxoSmithKline, Starpharma, ReceptoPharm, and more.
• Emerging … , Maruho, AiCuris, Sanofi, GlaxoSmithKline, Starpharma, ReceptoPharm, and more.
• Key …
-
Medicxi and Starpharma create Petalion Therapeutics to develop novel dendrimer-based treatments (ASX Announcement)
09 Apr 2024 17:21 GMT
… therapies in oncology, utilising Starpharma’s proprietary DEP dendrimer platform … created by Medicxi and Starpharma. Leveraging Starpharma’s world-leading technology … strategic partnership, which combines Starpharma’s expertise in developing dendrimer …
About
© 1995-2025